
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is positioned for strong growth, underscored by its robust cash position of approximately €16.7 billion, which provides significant financial flexibility to support ongoing and future development initiatives. The company's diversified oncology pipeline, including promising candidates like pumitamig and the adjusted ROSETTA-LUNG-02 study, highlights its commitment to advancing innovative therapies, bolstering the potential for meaningful upside in 2026. Additionally, anticipated positive interim Phase 3 data for its gotistobart treatment in squamous NSCLC further solidifies BioNTech's prospects, especially as it pivots towards becoming a fully integrated oncology company.
Bears say
The financial outlook for BioNTech is negatively impacted by a projected decline in COVID vaccine revenues, anticipating a 24% decrease in FY26, which raises concerns about the company's cash flow to support its research and development initiatives in oncology. Additionally, challenges such as lower than expected manufacturing capacity for personalized therapeutics and potential delays in advancing oncology programs could hinder revenue generation and materially affect future financial forecasts. Furthermore, the company faces significant risks, including negative clinical data, slow market uptake, and various regulatory and commercial uncertainties, all of which contribute to an overall pessimistic view of its financial trajectory.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares